Autolus Therapeutics to Amend Lease at Nucleus Manufacturing Facility in UK
Autolus Therapeutics Plc (AUTL): The Best Multibagger Penny Stock of 2025?
Autolus Therapeutics to Present Tumor Burden-Guided Dosing Data at SOHO 2024
Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Monday Trading
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Announces Target Price $11
Truist Financial analyst Asthika Goonewardene maintains $Autolus Therapeutics(AUTL.US)$ with a buy rating, and sets the target price at $11.According to TipRanks data, the analyst has a success rate
Analysts Conflicted on These Healthcare Names: Autolus Therapeutics (AUTL), DaVita (DVA) and Bruker (BRKR)
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
Autolus Therapeutics (NASDAQ:AUTL) Is In A Good Position To Deliver On Growth Plans
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading
Buy Rating Affirmed for Autolus Therapeutics Amid Strong Commercial Prospects and Solid Financials
Autolus Therapeutics (AUTL) Gets a Buy From Truist Financial
Autolus Therapeutics | 10-Q: Q2 2024 Earnings Report
Positive Outlook for Autolus Therapeutics With Upcoming Obe-cel Approvals and Promising Clinical Trials
Autolus Therapeutics Q2 EPS $(0.22) Misses $(0.19) Estimate, Company Exits Quarter With Cash & Equivalents Worth $705.9M
Autolus Therapeutics 2Q Loss/Shr 22c >AUTL
Here Is the Next Potential Market Catalyst
Autolus Therapeutics Q2 2024 Earnings Preview